Navigation Links
Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
Date:5/15/2008

BALTIMORE, May 15 /PRNewswire/ -- Lentigen Corporation announced today that it has received four National Institutes of Health (NIH) small business innovation research (SBIR) grants to collaborate with leading scientists. Through these grants, Lentigen will apply its proprietary lentiviral vector (LV) technology to the development of novel immunotherapeutic treatments for diseases of high unmet medical need:

-- Melanoma, with Michael Nishimura, Ph.D, Associate Professor of Surgery,

Medical University of South Carolina

-- Hepatitis C virus (HCV) infection, also with Dr. Nishimura

-- Epstein-Barr virus (EBV)-related diseases, with Adrian Wiestner,

M.D./Ph.D., Principal Investigator, National Cancer Institute

-- Chronic lymphocytic leukemia (CLL), also with Dr. Wiestner

Together with its collaborators, Lentigen will develop lentiviral vectors designed to target specific cells related to each of these diseases. For melanoma, HCV, and EBV, the vectors will transduce T cells, which play a central role in cell-mediated immunity, with proteins known as T cell receptors (TCRs) that have been engineered to attack the targeted disease. For CLL, the vectors will carry weakened cells of this cancer combined with other substances designed to trigger an immune response.

"These innovation research grants are enabling us to extend the application of our lentiviral vector technology to a wider range of diseases while working with distinguished researchers to address the urgent need for novel biotherapeutics and vaccines in areas of high unmet medical need," said Tim Ravenscroft, Lentigen's CEO.

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit http://www.lentigen.com http://www.lentigen.com/

Lentigen Media Contact:

Gregory Tiberend

gtiberend@rlcinc.com

Meghan Feeks

mfeeks@rlcinc.com

Richard Lewis Communications, Inc.

212-827-0020


'/>"/>
SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
2. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
3. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
4. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
5. VIRxSYS and Lentigen Announce Litigation Settlement
6. Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards
7. Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Triple-S Management Corporation Appoints New Non-Executive Chairman to Board; Adds New Director
9. Genaera Corporation Announces First Quarter Financial Results
10. EUSA Pharma Completes Acquisition Of Cytogen Corporation
11. Pharmos Corporation Reports 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, Product ... and Geography - Global Forecast to 2022", published by ... USD 2.94 Billion by 2022, at a CAGR of ... 70 market data Tables and 94 Figures spread through ...
(Date:4/28/2016)... Windsor, Connecticut (PRWEB) , ... April 28, 2016 ... ... Morris Group, Inc., will hold an open house for regional manufacturers at its ... and displays from Tsugami, Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 ...
(Date:4/27/2016)... British Columbia , April 27, 2016 /PRNewswire/ ... oder "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( ... im Anschluss an ihre Pressemitteilung vom 13. August ... erhalten hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten ... 4.000.000 Kanadische Dollar zu bringen. Davon wurden 157.900.000 ...
(Date:4/27/2016)... , ... April 27, 2016 , ... ... simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing ... disease and testing novel treatments in small animal subjects. Simultaneous PET/MRI imaging offers ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... LegacyXChange, Inc. (OTC: LEGX ... Protect are pleased to announce our successful effort to ... of writing instruments, ensuring athletes signatures against counterfeiting and ... athletes on LegacyXChange will be assured of ongoing proof ... Bill Bollander , CEO states, "By inserting ...
Breaking Biology News(10 mins):